The global pyelonephritis drug market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). A kidney infection, commonly known as pyelonephritis, is a form of urinary tract infection characterized by inflammation of one or both kidneys. Bacteria or a virus causes the illness, which usually starts in the urinary bladder and spreads to one or both kidneys. Confusion and back pain, chills and high fever, nausea and vomiting, back, side, and groyne discomfort, and painful urination are all signs or symptoms of pyelonephritis, which might vary based on age. Kidney stones, a weaker immune system, anatomical abnormalities with the urinary tract, urine reflux issues, and nerve damage surrounding the bladder are all some factors that cause pyelonephritis. Owing to the high prevalence and incidence rates of pyelonephritis problems around the world, the global pyelonephritis treatment market is expected to rise rapidly during the forecast period. Each year, over 200,000 hospitalizations for acute pyelonephritis are reported in the US. As a result, the global pyelonephritis treatment market is likely to be driven by a huge population base with a kidney infection during the forecast period.
Get Free Sample link @ https://www.omrglobal.com/request-sample/pyelonephritis-drug-market
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including partnerships and collaborations, mergers and acquisitions, geographical expansion, and new product launches, to remain competitive in the marketplace. For instance, in October 2021, Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases, announced that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for approval of tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis, caused by susceptible microorganisms.
Full report of Pyelonephritis Drug Market available @ https://www.omrglobal.com/industry-reports/pyelonephritis-drug-market
Market Coverage
Segment Covered-
- By Product Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Merck & Co, Inc., and AstraZeneca plc, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Pyelonephritis Drug Market Report by Segment
By Product Type
- Finafloxacin
- Fosfomycin Tromethamine
- Nacubactam
- Plazomicin Sulfate
- Others
By Application
- Hospital
- Clinic
- Others
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/pyelonephritis-drug-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.